company background image
CTLT

CatalentNYSE:CTLT Stock Report

Market Cap

US$21.0b

7D

-7.4%

1Y

28.4%

Updated

04 Dec, 2021

Data

Company Financials +
CTLT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance4/6
Financial Health3/6
Dividends0/6

CTLT Stock Overview

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide.

Catalent Competitors

Viatris

NasdaqGS:VTRS

US$14.8b

Procaps Group

NasdaqGM:PROC

US$1.1b

Thermo Fisher Scientific

NYSE:TMO

US$250.7b

WuXi AppTec

SHSE:603259

CN¥419.3b

Price History & Performance

Summary of all time highs, changes and price drops for Catalent
Historical stock prices
Current Share PriceUS$122.47
52 Week HighUS$142.64
52 Week LowUS$91.87
Beta1.32
1 Month Change-9.96%
3 Month Change-12.74%
1 Year Change28.38%
3 Year Change237.20%
5 Year Change399.06%
Change since IPO512.66%

Recent News & Updates

Nov 24
Calculating The Fair Value Of Catalent, Inc. (NYSE:CTLT)

Calculating The Fair Value Of Catalent, Inc. (NYSE:CTLT)

Today we will run through one way of estimating the intrinsic value of Catalent, Inc. ( NYSE:CTLT ) by taking the...

Oct 22
It Looks Like Shareholders Would Probably Approve Catalent, Inc.'s (NYSE:CTLT) CEO Compensation Package

It Looks Like Shareholders Would Probably Approve Catalent, Inc.'s (NYSE:CTLT) CEO Compensation Package

We have been pretty impressed with the performance at Catalent, Inc. ( NYSE:CTLT ) recently and CEO John Chiminski...

Oct 16
Is Catalent (NYSE:CTLT) Using Too Much Debt?

Is Catalent (NYSE:CTLT) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Shareholder Returns

CTLTUS PharmaceuticalsUS Market
7D-7.4%-2.3%-2.7%
1Y28.4%11.6%16.6%

Return vs Industry: CTLT exceeded the US Pharmaceuticals industry which returned 12.4% over the past year.

Return vs Market: CTLT exceeded the US Market which returned 19.4% over the past year.

Price Volatility

Is CTLT's price volatile compared to industry and market?
CTLT volatility
CTLT Average Weekly Movement3.8%
Pharmaceuticals Industry Average Movement9.4%
Market Average Movement6.1%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: CTLT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: CTLT's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200717,300John Chiminskihttps://www.catalent.com

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Catalent Fundamentals Summary

How do Catalent's earnings and revenue compare to its market cap?
CTLT fundamental statistics
Market CapUS$20.97b
Earnings (TTM)US$544.00m
Revenue (TTM)US$4.18b

38.5x

P/E Ratio

5.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CTLT income statement (TTM)
RevenueUS$4.18b
Cost of RevenueUS$2.75b
Gross ProfitUS$1.43b
ExpensesUS$883.00m
EarningsUS$544.00m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)3.18
Gross Margin34.16%
Net Profit Margin13.02%
Debt/Equity Ratio94.0%

How did CTLT perform over the long term?

See historical performance and comparison

Valuation

Is Catalent undervalued compared to its fair value and its price relative to the market?

19.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CTLT ($122.47) is trading below our estimate of fair value ($151.47)

Significantly Below Fair Value: CTLT is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: CTLT is poor value based on its PE Ratio (38.5x) compared to the US Pharmaceuticals industry average (23.1x).

PE vs Market: CTLT is poor value based on its PE Ratio (38.5x) compared to the US market (16.9x).


Price to Earnings Growth Ratio

PEG Ratio: CTLT is poor value based on its PEG Ratio (2.6x)


Price to Book Ratio

PB vs Industry: CTLT is overvalued based on its PB Ratio (5.2x) compared to the US Pharmaceuticals industry average (2.7x).


Future Growth

How is Catalent forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

15.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTLT's forecast earnings growth (15.1% per year) is above the savings rate (2%).

Earnings vs Market: CTLT's earnings (15.1% per year) are forecast to grow faster than the US market (14.1% per year).

High Growth Earnings: CTLT's earnings are forecast to grow, but not significantly.

Revenue vs Market: CTLT's revenue (9.2% per year) is forecast to grow slower than the US market (10% per year).

High Growth Revenue: CTLT's revenue (9.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CTLT's Return on Equity is forecast to be low in 3 years time (14.4%).


Past Performance

How has Catalent performed over the past 5 years?

40.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CTLT has a large one-off gain of $139.0M impacting its September 30 2021 financial results.

Growing Profit Margin: CTLT's current net profit margins (13%) are higher than last year (7.6%).


Past Earnings Growth Analysis

Earnings Trend: CTLT's earnings have grown significantly by 40.9% per year over the past 5 years.

Accelerating Growth: CTLT's earnings growth over the past year (117.6%) exceeds its 5-year average (40.9% per year).

Earnings vs Industry: CTLT earnings growth over the past year (117.6%) exceeded the Pharmaceuticals industry 12.2%.


Return on Equity

High ROE: CTLT's Return on Equity (13.6%) is considered low.


Financial Health

How is Catalent's financial position?


Financial Position Analysis

Short Term Liabilities: CTLT's short term assets ($3.9B) exceed its short term liabilities ($1.1B).

Long Term Liabilities: CTLT's short term assets ($3.9B) do not cover its long term liabilities ($4.7B).


Debt to Equity History and Analysis

Debt Level: CTLT's net debt to equity ratio (47.9%) is considered high.

Reducing Debt: CTLT's debt to equity ratio has reduced from 304.8% to 94% over the past 5 years.

Debt Coverage: CTLT's debt is not well covered by operating cash flow (10.8%).

Interest Coverage: CTLT's interest payments on its debt are well covered by EBIT (6.6x coverage).


Balance Sheet


Dividend

What is Catalent current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CTLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CTLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTLT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTLT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTLT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

John Chiminski (57 yo)

12.75yrs

Tenure

US$12,581,139

Compensation

Mr. John R. Chiminski serves as Independent Director at Berkeley Lights, Inc. since May 14, 2021. Mr. Chiminski has been the Chief Executive Officer at Catalent, Inc. since March 2009 and has been its Chai...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD12.58M) is about average for companies of similar size in the US market ($USD11.16M).

Compensation vs Earnings: John's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: CTLT's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: CTLT's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CTLT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.


Top Shareholders

Company Information

Catalent, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Catalent, Inc.
  • Ticker: CTLT
  • Exchange: NYSE
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$20.965b
  • Shares outstanding: 171.19m
  • Website: https://www.catalent.com

Number of Employees


Location

  • Catalent, Inc.
  • 14 Schoolhouse Road
  • Somerset
  • New Jersey
  • 8873
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/04 00:11
End of Day Share Price2021/12/03 00:00
Earnings2021/09/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.